Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A prospective, single-arm, phase II trial of Adebrelimab combined with bevacizumab and
albumin paclitaxel in advanced non-squamous non-small cell lung cancer after first-line
immunotherapy progression.